SCHEMBL696198

SCHEMBL696198

COC(=O)[C@@H]1C[C@@H](Sc2ccc(C)cc2C)CN1C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
PTPN1 P18031 1/20 0.40
PDE4B Q07343 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
EPHX2 P34913 1/20 0.38
P2RX3 P56373 2/20 0.38
HDAC8 Q9BY41 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GPR119 Q8TDV5 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15184109 0.90 CYP1A2 (0.46) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL689919 0.90 P2RX3 (0.43) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL2059282 0.84 CYP1A2 (0.46) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL6842749 0.84 CYP1A2 (0.46) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL12589789 0.84 CYP1A2 (0.46) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL15169964 0.81 ALDH1A1 (0.41) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL696886 0.81 NR1H2 (0.42) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL14974696 0.81 NR1H2 (0.42) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL2685355 0.81 NR1H2 (0.42) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL716249 0.81 CCNT1 (0.40) CYP1A2POLBCYP3A4CYP2C19NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CYP1A2 936/4885POLB 3726/4885CYP3A4 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.